Syndax Pharmaceuticals Inc Logo

Syndax Pharmaceuticals Inc

Biopharma firm developing and commercializing first-in-class therapies for cancer patients.

SNDX | US

Overview

Corporate Details

ISIN(s):
US87164F1057
LEI:
Country:
United States of America
Address:
730 THIRD AVENUE, 10017 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that develops and commercializes innovative therapies for cancer patients. The company focuses on advancing first-in-class treatments in areas of significant unmet medical need, with a particular emphasis on conditions such as acute leukemia. Syndax's mission is to discover and develop transformative drugs by leveraging scientific approaches in epigenetics and immunomodulation. The firm aims to obtain regulatory approval and commercialize these novel therapies to extend and improve the lives of people with cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Syndax Pharmaceuticals Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Syndax Pharmaceuticals Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Syndax Pharmaceuticals Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.